OvaScience Suffers FDA Setback on Augment Fertility

OvaScience Suffers FDA Setback on Augment Fertility Play

Sept. 11 (Bloomberg) -- Bloomberg's Olivia Sterns reports that OvaScience has received an "untitled" letter from the FDA on Augment and suspended U.S. enrollment of product candidates in "On The Markets." She speaks on Bloomberg Television's "Market Makers."

blog comments powered by Disqus